title: [Tolerance of bevacizumab therapy in systemic sclerosis-associated pulmonary arterial hypertension: A case report].
abstract: BACKGROUND
  No data is available regarding the safety of bevacizumab, an anti-vascular endothelial growth factor-A (VEGF-A) antibody, in patients with pulmonary arterial hypertension (PAH), a condition in which VEGF seems to play a significant and probably protective role.
  
  
  METHODS
  We report a patient with a history of systemic sclerosis-associated PAH, stable under bosentan therapy. She was diagnosed with metastatic cervical epidermoid carcinoma and treated by two successive cytotoxic chemotherapy regimens. As these treatments failed to control disease progression, she was started on anti-angiogenic therapy: 3 infusions of bevacizumab 15 mg/kg were administered. Over the course of this treatment, no change in the clinical status or echocardiography parameters was noted.
  
  
  CONCLUSIONS
  This observation suggests that, under careful clinical and echocardiographic follow-up, bevacizumab therapy can be well tolerated in case of stable and moderate PAH. Decision of treatment should be taken cautiously, as the possibility of PAH worsening is not excluded.
authors.affiliation: Université de Lille, 59000 Lille, France; Inserm, U995, 59000 Lille, France; Département de médecine interne et immunologie clinique, hôpital Claude-Huriez, CHRU de Lille, rue Michel-Polonovski, 59037 Lille cedex, France; Centre national de référence maladies systémiques et auto-immunes rares (sclérodermie systémique), 59000 Lille, France; Fédératif hospitalo-universitaire immune-mediated inflammatory diseases and targeted therapies (FHU IMMINeNT), 59000 Lille, France. Electronic address: sebastien_sanges@msn.com.
authors.forename: S
authors.initials: S
authors.lastname: Sanges
authors.affiliation: Université de Lille, 59000 Lille, France; Département d'oncologie médicale, CHRU de Lille, 59000 Lille cedex, France.
authors.forename: C
authors.initials: C
authors.lastname: Desauw
authors.affiliation: Université de Lille, 59000 Lille, France; Département de cardiologie, CHRU de Lille, 59000 Lille cedex, France.
authors.forename: P
authors.initials: P
authors.lastname: de Groote
authors.affiliation: Université de Lille, 59000 Lille, France; Département de cardiologie, CHRU de Lille, 59000 Lille cedex, France.
authors.forename: M
authors.initials: M
authors.lastname: Fertin
authors.affiliation: Université de Lille, 59000 Lille, France; Département de cardiologie, CHRU de Lille, 59000 Lille cedex, France.
authors.forename: N
authors.initials: N
authors.lastname: Lamblin
authors.affiliation: Université de Lille, 59000 Lille, France; Département de pneumologie, CHRU de Lille, 59000 Lille cedex, France.
authors.forename: J-F
authors.initials: JF
authors.lastname: Bervar
authors.affiliation: Université de Lille, 59000 Lille, France; Département de médecine interne et immunologie clinique, hôpital Claude-Huriez, CHRU de Lille, rue Michel-Polonovski, 59037 Lille cedex, France; Centre national de référence maladies systémiques et auto-immunes rares (sclérodermie systémique), 59000 Lille, France; Fédératif hospitalo-universitaire immune-mediated inflammatory diseases and targeted therapies (FHU IMMINeNT), 59000 Lille, France.
authors.forename: P-Y
authors.initials: PY
authors.lastname: Hatron
authors.affiliation: Université de Lille, 59000 Lille, France; Inserm, U995, 59000 Lille, France; Département de médecine interne et immunologie clinique, hôpital Claude-Huriez, CHRU de Lille, rue Michel-Polonovski, 59037 Lille cedex, France; Centre national de référence maladies systémiques et auto-immunes rares (sclérodermie systémique), 59000 Lille, France; Fédératif hospitalo-universitaire immune-mediated inflammatory diseases and targeted therapies (FHU IMMINeNT), 59000 Lille, France.
authors.forename: E
authors.initials: E
authors.lastname: Hachulla
authors.affiliation: Université de Lille, 59000 Lille, France; Inserm, U995, 59000 Lille, France; Département de médecine interne et immunologie clinique, hôpital Claude-Huriez, CHRU de Lille, rue Michel-Polonovski, 59037 Lille cedex, France; Centre national de référence maladies systémiques et auto-immunes rares (sclérodermie systémique), 59000 Lille, France; Fédératif hospitalo-universitaire immune-mediated inflammatory diseases and targeted therapies (FHU IMMINeNT), 59000 Lille, France.
authors.forename: D
authors.initials: D
authors.lastname: Launay
mesh_terms: D000368:Aged; D000068258:Bevacizumab / Q000627:therapeutic use*; D002294:Carcinoma, Squamous Cell / Q000150:complications / Q000188:drug therapy; D005260:Female; D006801:Humans; D006976:Hypertension, Pulmonary / Q000188:drug therapy* / Q000209:etiology*; D012595:Scleroderma, Systemic / Q000150:complications* / Q000188:drug therapy*; D016896:Treatment Outcome; D014594:Uterine Neoplasms / Q000150:complications / Q000188:drug therapy
chemical_list: D000068258:Bevacizumab
keywords: Angiogenic inhibitors; Bevacizumab; Bévacizumab; Hypertension artérielle pulmonaire; Inhibiteurs de l’angiogenèse; Pulmonary arterial hypertension; Sclérodermie systémique; Systemic sclerosis; VEGF